demonstrated that circulating CD4+ T‐cell subsets (consisting of CXCR3−CCR4−CCR6+ as well CXCR3+CCR4−CCR6+ cells) were observed to be significantly correlated with PFS and OS of patients with NSCLC receiving anti‐PD‐1 therapy, as well as, correlated with the infiltration of CD4+ T cell in TME. This evidence concerns the gene CD4 and non-small cell lung carcinoma.